SAFC forms partnership with CatScI to broaden catalysis services

SAFC Commercial, the custom manufacturing services business unit of Sigma-Aldrich in the US, has entered into a services agreement with CatScI, a UK-based catalysis company.

CatSci focuses on maximising yield, optimising quality, reducing waste and minimising chemical development costs through reaction understanding.

SAFC commercial says its customers will immediately benefit from the relationship through rapid access to new reactions, homogeneous and heterogeneous catalysis, biocatalysts, solvent selection and process development, in addition to metal removal, recovery and recycling services.

'The strategic partnership combines CatScI’s extensive expertise in catalysed reactions and complex chemical processes with SAFC’s strength in process development, scale-up and manufacturing of high-value products,' said Andreas Weiler, Head of Global Strategic Marketing for Contract Manufacturing Services & Solutions at SAFC.

'As a combined offering, we are able to provide customers with a single source for high-quality, high-value fundamental research, development, scale-up and manufacture, with additional process development resources for customers to screen projects more quickly, and efficiently maximise catalyst reactions using the appropriate ligands, solvents and science.'

According to Simon Tyler, Commercial Director at CatScI, the collaboration builds naturally on each company's strong foundation.

As a combined offering, we are able to provide customers with a single source for high-quality, high-value fundamental research

'CatScI’s technology platform and methodology is differentiated to provide unique research and development in a cost- and time-efficient manner,' he said.

'Customers can take advantage of our expertise in both chemo- and bio-catalysis for the suggestion, screening, selection, development and optimisation of reactions and processes. In essence, we provide innovative solutions to all types of challenging synthetic chemistry problems.'

Approximately 90% of chemicals now require the use of catalytic processes in their manufacture, says SAFC. With chemical targets becoming more complex and the average number of transformations required to synthesise an active pharmaceutical ingredient (API) continuing to climb and currently averaging 12 synthetic steps, industrial chemists look increasingly to employ catalysis to achieve concise and economical processes in R&D and production.

CatScI employs a combination of computational, statistical and synthetic methods and advanced technology for the rational exploration of reaction space, with access to hundreds of different catalysts and has extensive experience in the investigation of the influence of the many experimental parameters at play.